T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) overview
T-cell acute lymphoblastic leukemia (T-ALL) is a type of blood cancer that affects T-cell lymphocytes, a type of white blood cell involved in the immune system’s function. T-ALL originates from immature T-cells in the bone marrow that fail to mature into normal functioning T-cells. These abnormal cells grow rapidly, crowding out normal blood cells (red blood cells, white blood cells, and platelets) in the bone marrow. T-ALL is more prevalent in children and adolescents than in adults. It accounts for approximately 15% of pediatric acute lymphoblastic leukemia (ALL) cases. The exact cause of T-ALL is not fully understood. However, certain risk factors have been identified, including genetic factors, exposure to high levels of radiation or certain chemicals, and certain genetic disorders or inherited syndromes.
See Also:
For a complete picture of PTSR and LoA scores for drugs in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
